The Future of Childhood Cancer Survivorship: Challenges and Opportunities for Continued Progress

Overview

Journal Pediatr Clin North Am

Specialty Pediatrics

Date 2020 Nov 2

PMID 33131544

Citations 11

Authors

Stephanie B Dixon

Eric J Chow

Lars Hjorth

Melissa M Hudson

Leontien C M Kremer

Lindsay M Morton

Paul C Nathan

Kirsten K Ness

Kevin C Oeffinger

Gregory T Armstrong

Affiliations

Soon will be listed here.

Abstract

As treatment evolves and the population who survive childhood cancer ages and increases in number, researchers must use novel approaches to prevent, identify and mitigate adverse effects of treatment. Future priorities include collaborative efforts to pool large cohort data to improve detection of late effects, identify late effects of novel therapies, and determine the contribution of genetic factors along with physiologic and accelerated aging among survivors. This knowledge should translate to individual risk prediction and prevention strategies. Finally, we must utilize health services research and implementation science to improve adoption of survivorship care recommendations outside of specialized pediatric oncology centers.

Citing Articles

Co-Design and Evaluation Protocol for the RECOVER Model of Care After Childhood Cancer Treatment.

Bradford N, Cashion C, Sharwood E, Rumble S, Condon P, Cossio D Healthcare (Basel). 2025; 13(5).

PMID: 40077016 PMC: 11899481. DOI: 10.3390/healthcare13050454.

Late Complications in Long-Term Childhood Cancer Survivors: What the Oral Health Professional Needs to Know.

Al-Ansari S, Stolze J, Bresters D, Brook A, Laheij A, Brand H Dent J (Basel). 2024; 12(1).

PMID: 38275678 PMC: 10813876. DOI: 10.3390/dj12010017.

Physical late effects of treatment among survivors of childhood cancer in low- and middle-income countries: a systematic review.

Wong K, Moskalewicz A, Nathan P, Gupta S, Denburg A J Cancer Surviv. 2024; .

PMID: 38183576 DOI: 10.1007/s11764-023-01517-8.

Impact of Volumetric Dosimetry on the Projected Cost of Radiation-Related Late Effects Screening After Childhood Cancer: A Real-World Cohort Analysis.

Cohen-Cutler S, Kaplan C, Olch A, Wong K, Malvar J, Constine L Oncologist. 2023; 28(9):e784-e792.

PMID: 37284853 PMC: 10485276. DOI: 10.1093/oncolo/oyad136.

Associations of Symptom Clusters and Health Outcomes in Adult Survivors of Childhood Cancer: A Report From the St Jude Lifetime Cohort Study.

Shin H, Dudley W, Bhakta N, Horan M, Wang Z, Bartlett T J Clin Oncol. 2022; 41(3):497-507.

PMID: 36166720 PMC: 9870227. DOI: 10.1200/JCO.22.00361.

References

Michailidou K, Beesley J, Lindstrom S, Canisius S, Dennis J, Lush M . Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet. 2015; 47(4):373-80. PMC: 4549775. DOI: 10.1038/ng.3242. View

Pollard J, Loken M, Gerbing R, Raimondi S, Hirsch B, Aplenc R . CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531. J Clin Oncol. 2016; 34(7):747-55. PMC: 4872025. DOI: 10.1200/JCO.2015.62.6846. View

Robison L, Hudson M . Survivors of childhood and adolescent cancer: life-long risks and responsibilities. Nat Rev Cancer. 2013; 14(1):61-70. PMC: 6425479. DOI: 10.1038/nrc3634. View

Chow E, Chen Y, Kremer L, Breslow N, Hudson M, Armstrong G . Individual prediction of heart failure among childhood cancer survivors. J Clin Oncol. 2014; 33(5):394-402. PMC: 4314592. DOI: 10.1200/JCO.2014.56.1373. View

Robison L, Armstrong G, Boice J, Chow E, Davies S, Donaldson S . The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research. J Clin Oncol. 2009; 27(14):2308-18. PMC: 2677920. DOI: 10.1200/JCO.2009.22.3339. View

Landier W, Chen Y, Namdar G, Francisco L, Wilson K, Herrera C . Impact of Tailored Education on Awareness of Personal Risk for Therapy-Related Complications Among Childhood Cancer Survivors. J Clin Oncol. 2015; 33(33):3887-93. PMC: 4652012. DOI: 10.1200/JCO.2015.62.7562. View

von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett T, Rizzari C . Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. J Clin Oncol. 2016; 34(36):4381-4389. DOI: 10.1200/JCO.2016.67.3301. View

Sutradhar R, Agha M, Pole J, Greenberg M, Guttmann A, Hodgson D . Specialized survivor clinic attendance is associated with decreased rates of emergency department visits in adult survivors of childhood cancer. Cancer. 2015; 121(24):4389-97. DOI: 10.1002/cncr.29679. View

Ness K, Kirkland J, Gramatges M, Wang Z, Kundu M, McCastlain K . Premature Physiologic Aging as a Paradigm for Understanding Increased Risk of Adverse Health Across the Lifespan of Survivors of Childhood Cancer. J Clin Oncol. 2018; 36(21):2206-2215. PMC: 6553838. DOI: 10.1200/JCO.2017.76.7467. View

10.

Wang Z, Wilson C, Easton J, Thrasher A, Mulder H, Liu Q . Genetic Risk for Subsequent Neoplasms Among Long-Term Survivors of Childhood Cancer. J Clin Oncol. 2018; 36(20):2078-2087. PMC: 6036620. DOI: 10.1200/JCO.2018.77.8589. View

11.

Zabih V, Kahane A, ONeill N, Ivers N, Nathan P . Interventions to improve adherence to surveillance guidelines in survivors of childhood cancer: a systematic review. J Cancer Surviv. 2019; 13(5):713-729. DOI: 10.1007/s11764-019-00790-w. View

12.

Caplin D, Smith K, Ness K, Hanson H, Smith S, Nathan P . Effect of Population Socioeconomic and Health System Factors on Medical Care of Childhood Cancer Survivors: A Report from the Childhood Cancer Survivor Study. J Adolesc Young Adult Oncol. 2016; 6(1):74-82. PMC: 5346913. DOI: 10.1089/jayao.2016.0016. View

13.

Winther J, Kenborg L, Byrne J, Hjorth L, Kaatsch P, Kremer L . Childhood cancer survivor cohorts in Europe. Acta Oncol. 2015; 54(5):655-68. DOI: 10.3109/0284186X.2015.1008648. View

14.

Hudson M, Ness K, Gurney J, Mulrooney D, Chemaitilly W, Krull K . Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA. 2013; 309(22):2371-2381. PMC: 3771083. DOI: 10.1001/jama.2013.6296. View

15.

Moslehi J, Salem J, Sosman J, Lebrun-Vignes B, Johnson D . Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018; 391(10124):933. PMC: 6668330. DOI: 10.1016/S0140-6736(18)30533-6. View

16.

Armstrong G, Kawashima T, Leisenring W, Stratton K, Stovall M, Hudson M . Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. J Clin Oncol. 2014; 32(12):1218-27. PMC: 3986385. DOI: 10.1200/JCO.2013.51.1055. View

17.

Price A, Spencer C, Donnelly P . Progress and promise in understanding the genetic basis of common diseases. Proc Biol Sci. 2015; 282(1821):20151684. PMC: 4707742. DOI: 10.1098/rspb.2015.1684. View

18.

Nathan P, Ness K, Mahoney M, Li Z, Hudson M, Ford J . Screening and surveillance for second malignant neoplasms in adult survivors of childhood cancer: a report from the childhood cancer survivor study. Ann Intern Med. 2010; 153(7):442-51. PMC: 3084018. DOI: 10.7326/0003-4819-153-7-201010050-00007. View

19.

Bhakta N, Liu Q, Ness K, Baassiri M, Eissa H, Yeo F . The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE). Lancet. 2017; 390(10112):2569-2582. PMC: 5798235. DOI: 10.1016/S0140-6736(17)31610-0. View

20.

Teepen J, van Leeuwen F, Tissing W, van Dulmen-den Broeder E, van den Heuvel-Eibrink M, van der Pal H . Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy. J Clin Oncol. 2017; 35(20):2288-2298. DOI: 10.1200/JCO.2016.71.6902. View